BRPI0513777A - composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo - Google Patents
composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmoInfo
- Publication number
- BRPI0513777A BRPI0513777A BRPI0513777-2A BRPI0513777A BRPI0513777A BR PI0513777 A BRPI0513777 A BR PI0513777A BR PI0513777 A BRPI0513777 A BR PI0513777A BR PI0513777 A BRPI0513777 A BR PI0513777A
- Authority
- BR
- Brazil
- Prior art keywords
- nitrogen
- formula
- salt
- compound
- ring
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000002393 azetidinyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 abstract 1
- 229940122931 Histamine H3 receptor inverse agonist Drugs 0.000 abstract 1
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 1
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- -1 aryl oxazole compounds Chemical class 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59119104P | 2004-07-26 | 2004-07-26 | |
| PCT/US2005/024883 WO2006019833A1 (en) | 2004-07-26 | 2005-07-14 | Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0513777A true BRPI0513777A (pt) | 2008-05-13 |
Family
ID=35134220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0513777-2A BRPI0513777A (pt) | 2004-07-26 | 2005-07-14 | composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7666871B2 (enExample) |
| EP (1) | EP1786790B1 (enExample) |
| JP (1) | JP4982367B2 (enExample) |
| CN (1) | CN1989115B (enExample) |
| AT (1) | ATE432926T1 (enExample) |
| AU (1) | AU2005275183B2 (enExample) |
| BR (1) | BRPI0513777A (enExample) |
| CA (1) | CA2575081C (enExample) |
| CY (1) | CY1109493T1 (enExample) |
| DE (1) | DE602005014786D1 (enExample) |
| DK (1) | DK1786790T3 (enExample) |
| ES (1) | ES2325865T3 (enExample) |
| MX (1) | MX2007001029A (enExample) |
| PL (1) | PL1786790T3 (enExample) |
| PT (1) | PT1786790E (enExample) |
| SI (1) | SI1786790T1 (enExample) |
| WO (1) | WO2006019833A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008301B2 (en) * | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| EP1848428A4 (en) | 2005-02-18 | 2012-04-18 | Neurogen Corp | THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGS |
| US7790720B2 (en) | 2005-03-31 | 2010-09-07 | Ucb Pharma, S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| AU2006316079B2 (en) | 2005-11-15 | 2012-03-29 | Otsuka Pharmaceutical Co., Ltd. | Oxazole compound and pharmaceutical composition |
| JP2009530274A (ja) | 2006-03-15 | 2009-08-27 | ワイス | ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン化合物 |
| EP2027086B1 (en) | 2006-05-19 | 2011-11-16 | Wyeth LLC | N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists |
| EP2024327A1 (de) * | 2006-05-19 | 2009-02-18 | Basf Se | Benzoylsubstituierte alanine |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PE20081152A1 (es) | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
| AR067549A1 (es) * | 2007-07-16 | 2009-10-14 | Wyeth Corp | Compuesto de oxazol,tiazol e imidazol, composicion farmaceutica que lo comprende , proceso para la preparacion del compuesto , uso del compuesto y metodos para la inhibicion del receptor h3 y para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina -3 (h3 |
| WO2009126782A1 (en) * | 2008-04-11 | 2009-10-15 | High Point Pharmaceuticals, Llc | Histamine h3 receptor ligands |
| US8383829B2 (en) * | 2008-04-15 | 2013-02-26 | Konica Minolta Holdings, Inc. | Electrochromic compound, electrode, and display element |
| SA110310332B1 (ar) * | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| MX2012015102A (es) | 2010-07-06 | 2013-05-01 | Astrazeneca Ab | Agentes terapeuticos 976. |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| RU2644769C2 (ru) | 2013-01-23 | 2018-02-14 | Астразенека Аб | Химические соединения |
| CN107406424B (zh) * | 2014-12-18 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 雌激素受体调节剂及其用途 |
| CA2988147C (en) | 2015-06-03 | 2023-06-13 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| LT3319959T (lt) | 2015-07-06 | 2021-12-27 | Alkermes, Inc. | Histono deacetilazės hetero-halogeno inhibitoriai |
| ES2909086T3 (es) | 2017-01-11 | 2022-05-05 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
| SG11202000970WA (en) | 2017-08-07 | 2020-02-27 | Rodin Therapeutics Inc | Bicyclic inhibitors of histone deacetylase |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3819037A1 (de) * | 1988-06-04 | 1989-12-14 | Hoechst Ag | 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden |
| AU674613B2 (en) * | 1993-09-28 | 1997-01-02 | Otsuka Pharmaceutical Co., Ltd. | Quinoxaline derivative as antidiabetic agent |
| WO2000064884A1 (en) * | 1999-04-26 | 2000-11-02 | Novo Nordisk A/S | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
| WO2002076925A2 (en) | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| BR0306980A (pt) | 2002-02-01 | 2004-11-09 | Novo Nordisk As | Composto, uso de um composto, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com o receptor de histamina h3 |
| US7332508B2 (en) | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| US7259262B2 (en) * | 2003-10-24 | 2007-08-21 | Hoffmann-La Roche Inc. | Arylazole derivatives, their manufacture and use as pharmaceutical agents |
-
2005
- 2005-07-14 WO PCT/US2005/024883 patent/WO2006019833A1/en not_active Ceased
- 2005-07-14 PT PT05773290T patent/PT1786790E/pt unknown
- 2005-07-14 BR BRPI0513777-2A patent/BRPI0513777A/pt not_active IP Right Cessation
- 2005-07-14 DK DK05773290T patent/DK1786790T3/da active
- 2005-07-14 CN CN200580024874XA patent/CN1989115B/zh not_active Expired - Fee Related
- 2005-07-14 CA CA2575081A patent/CA2575081C/en not_active Expired - Fee Related
- 2005-07-14 AU AU2005275183A patent/AU2005275183B2/en not_active Ceased
- 2005-07-14 JP JP2007523605A patent/JP4982367B2/ja not_active Expired - Fee Related
- 2005-07-14 AT AT05773290T patent/ATE432926T1/de active
- 2005-07-14 PL PL05773290T patent/PL1786790T3/pl unknown
- 2005-07-14 SI SI200530741T patent/SI1786790T1/sl unknown
- 2005-07-14 MX MX2007001029A patent/MX2007001029A/es active IP Right Grant
- 2005-07-14 US US11/572,283 patent/US7666871B2/en not_active Expired - Fee Related
- 2005-07-14 DE DE602005014786T patent/DE602005014786D1/de not_active Expired - Lifetime
- 2005-07-14 EP EP05773290A patent/EP1786790B1/en not_active Expired - Lifetime
- 2005-07-14 ES ES05773290T patent/ES2325865T3/es not_active Expired - Lifetime
-
2009
- 2009-08-06 CY CY20091100831T patent/CY1109493T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008507579A (ja) | 2008-03-13 |
| MX2007001029A (es) | 2007-04-12 |
| ES2325865T3 (es) | 2009-09-22 |
| CN1989115A (zh) | 2007-06-27 |
| AU2005275183B2 (en) | 2011-03-17 |
| JP4982367B2 (ja) | 2012-07-25 |
| EP1786790B1 (en) | 2009-06-03 |
| CN1989115B (zh) | 2012-03-21 |
| DE602005014786D1 (de) | 2009-07-16 |
| DK1786790T3 (da) | 2009-07-20 |
| ATE432926T1 (de) | 2009-06-15 |
| SI1786790T1 (sl) | 2009-10-31 |
| PT1786790E (pt) | 2009-08-18 |
| CA2575081A1 (en) | 2006-02-23 |
| EP1786790A1 (en) | 2007-05-23 |
| AU2005275183A1 (en) | 2006-02-23 |
| CY1109493T1 (el) | 2014-08-13 |
| US7666871B2 (en) | 2010-02-23 |
| WO2006019833A1 (en) | 2006-02-23 |
| CA2575081C (en) | 2013-05-07 |
| PL1786790T3 (pl) | 2009-10-30 |
| US20070197604A1 (en) | 2007-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109493T1 (el) | Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις | |
| NZ588121A (en) | Novel estrogen receptor ligands | |
| WO2005080384A3 (en) | Benzimidazole derivative and use as aii receptor antagonist | |
| AR035548A1 (es) | Compuestos organicos | |
| BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
| TW200637550A (en) | Thiazole-4-carboxamide derivatives as mGluR5 antagonists | |
| EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
| ATE457988T1 (de) | A2a-adenosin-rezeptor-antagonisten | |
| EA200970705A1 (ru) | Новые фармацевтические композиции | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| EA200970704A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ | |
| BRPI0512058A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto | |
| AR046085A1 (es) | Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico | |
| MY139612A (en) | Benzoxazine derivatives as 5-th6 modulators and uses thereof | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| AR058701A1 (es) | Derivados de piracinil-s-espiro-oxacinoquinolin-pirimidin-triona como agentes antibacterianos | |
| MX2007005709A (es) | Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos. | |
| ES2197003A1 (es) | Nuevos compuestos antagonistas de integrinas alfa. | |
| ATE541839T1 (de) | Pyrrolidiniumderivate als m3-muskarinische rezeptoren | |
| BRPI0415109A (pt) | compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda | |
| JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| DE602005007064D1 (de) | Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors | |
| EA200702612A1 (ru) | Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт | |
| JOP20220082A1 (ar) | مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
| EA200401077A1 (ru) | 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |